stockrow
Saturday 7 November 2026
Export ALGS’s income statement to Excel — free account
Aligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
Aligos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 million, down 44.6% from fiscal 2024.
- Revenue
- +287.2%
- EPS
- +31.3%
- Free cash flow
- +105.9%
Quarter to September 2026, against a year earlier
4.09
0.42
−9.31%
Follow ALGS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 2 | 3 |
| (196.92%) | (121.86%) | (113.59%) | (159.46%) | ||
| (30.50%) | (83.92%) | (75.57%) | (84.46%) | ||
ROIC |
0.00% | 0.00% | (3,379.28%) | (400.91%) | |
Return on Tangible Assets |
(38.10%) | (238.33%) | (216.31%) | (406.78%) | |
Average Days of Receivables |
0.00 | 0.00 | 321.69 | 0.00 | |
Free Cash Flow per Share |
(8.39) | (8.19) | (9.06) | (6.54) | |
Free Cash Flow |
(82.94) | (85.18) | (94.52) | (68.37) | |
Capital Expenditures |
(0.44) | (0.46) | (0.35) | — | |
| Other line items | |||||
Cash ROIC |
(63.07%) | (98.06%) | (151.71%) | (604.74%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.04 | 0.06 | |
Research and Development Expense of Revenue |
3,177.17% | 1,664.25% | 280.40% | 247.67% | |
Selling, General and Administrative Expense of Revenue |
947.76% | 469.14% | 70.23% | 67.87% | |
Share Based Compensation of Revenue |
230.74% | 114.75% | 17.78% | 16.10% | |
Operating CF/Net income |
3.41 | 0.94 | 1.24 | 1.03 | |
Depreciation/Fixed assets |
(0.67) | (0.87) | (0.42) | 0.00 | |
Capex/Depreciation |
0.35 | 0.33 | 0.63 | — | |
Revenue per Share |
0.22 | 0.45 | 3.02 | 3.22 | |
Operating CF per Share |
(8.35) | (8.14) | (9.03) | (6.54) | |
Capex per Share |
(0.04) | (0.04) | (0.03) | 0.00 | |
Capex to Sales |
0.20 | 0.10 | 0.01 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026